Introduction

C HRONIC KIDNEY DISEASE (CKD) is a widespreadmedica1
condition that for many patients \Vill inevitably progresses toward end stage renal disease despite tnedical intervention [l] . Even \Vith its often unrelenting course, CKD is relatively asymptomatic for the afflicted patient who must endure lifelong treat1nent \vith tangible side effects. There is an urgent need for new therapies that can stop or reverse the course of chronic kidney disease \Vith minimal side-effect burden on the patient. Small interfering RNA (siRNA) nanoparticles are novel therapeutic entities in clinical development that could be useful for this indication. siRNA nanoparticles combine the tissue specificity characteristic of nanoparticle therapeutics [2] with gene-specific silencing effects of siRNA [3] . This rational combination of therapeutic modalities is a promising strategy for diseases, such as CKD, that \Vould benefit from highly specific tissue targeting \Vith minimal off-target effects.
Several reports have highlighted the kidney glomerulus as an accessible target for nanoparticle based therapeutics [4] . Choi et al., have demonstrated that intravenously (i.v.) administered PEGylated gold nanoparticles (under IOOnm) have a restricted kidney deposition within the tnesangium [5] . Liao et al. sho\ved that i.v. TRX-20-prednisolone loaded liposome treatments reduced glomerular mesangial immunoglobin A (lgA) and C3 depositions in a mouse model of IgA nephritis (ddY mice) [6] . Morimoto et al. reported that a single i.v. injection of TRX-20-prednisolone loaded liposomes given to a rat model of human mesangial proliferative glomerulonephritis (anti-Thy-1 nephritis model) reduced the total glomerular cell number and level of a-smooth muscle actin-positive cells at a n1arkedly reduced dose con1pared \Vith daily injections of a prednisolone saline solution [7] . Kan1ps et al. demonstrated that i.v. doses of dexamethasonecontaining monoclonal anti-E-selectin antibody-targeted immunoliposomes (Dexa-AbEsel liposomes) decreased plasma blood urea nitrogen levels, g1omen1lar proinflamrnatory gene levels, and the percentage of crescent glomeruli in an antiglomerular basement 1nembrane glomendonephritis mouse model. Notably, Dexa-AbEseI liposome treatment did not result in elevation of plasma glucose levels, as \vas observed with administration of free dexamethasone [SJ. Suana et al. sho\ved that single i.v. administration of lo\v dose mycophenolate mofetil-OX7-immunoliposomes (MMF-OX7-1Ls) resulted in less severe nepluitis, with decreased 1ne-sangial expansion, compared with free MMF in rat antithymocyte antigen I (Thyl.l) nephritis [9] . Importantly, liposomal delivery of MMF required only half the s\andard total MMF dose to achieve these therapeutic effects.
Altogether, these literature examples demonstrate feasibility of nanoparticle therapeutic delivery to the glomerulus with reduced off-target effects and toxicities.
Only t\vo reports of systemically adn1inistered siRNA delivery to the glome1ulus have been reported. Shimizu et al. have repo1ted "proof of principle" results showing that a siRNAfcationic polymer (PLLg) delivery system can reach the glomerulus follo\ving intraperitoneal administration [10] .
Administration of these nanocarriers to lpr mice (mouse lupus nephritis model) resulted in the decrease of MAPKl expression and reduced sclerosis \Vithin the nephritic glomeruli of these mice. Hauser et al have demonstrated that coupling of siRNA to an antibody can be used for specific siRNA delivery to podocytes following i.v. administration [11] .
\Ve have previously reported that cyclodextrin-containing siRNA nanoparticles (siRNNCDP-NPs) quickly accun1ulate in the glomemlar basement membrane after i.v. administration [12] . This nanoparticle formulation (Fig. I ) of siRNA (not chemically modified) \Vith a cationic, cyclodextrincontaining polyn1er (CDP)-based delivery vehicle (clinical version denoted CALAA-01) has been sho\vn to accunuilate in human tumors and deliver functional siRNA from a systemic, i.v. infusion [13] . Given its glomerular localization and its clinical utility, \Ve decided to explore the potential of this siRNNCDP-NP for siRNA delivery to the mesangium. Here, we test the hypothesis that the siRNA/CDP-NPs can deliver siRNA to the glomen1lar mesangium to facilitate the knockdo\vn of target genes in this tissue compartment.
Materials and Methods
Small interfering RNA/CDP nanoparticle formulation
siRNA nanoparticles were formed by using cyclodextrincontaining polycations (CDP), adamantane-polyethylene glycol (AD-PEG), AD-PEG-mannose, and AD-PEG-transferrin as previously described (precomplexation) [14] . Nanoparticles \Vere formed in 5% glucose in deionized water at a charge ratio of 3 +/-and a siRNA concentration of 2n1g/mL unless othenvise indicated. T\venty-one base pair unmodified and cyanine 3 (Cy3)-labeled oligos were purchased from Qiagen. Sense strand sequences are as follo\vs: siRNA targeting enhanced green fluorescent protein (EGFP) (5'-GGCUACG UCCAGGAGCGCACC-3') from Novina et al. (2002) [15] , control siRNA (siCON) (5'-UAGCGACUAAACACAUCAA UU-3'), si1RACE (5'-CCUGCGAACACACAAGCUCCU-3').
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Synthesis of AF350-labeled CDP
CDP (30mg) and Alexa Fluor® 350 succinimidyl ester (5 mg, Invitrogen) \Vere transferred to a :flask \vrapped in aluminum foil and dried under vacuum for 2 hours; 0.5 mL of anhydrous dimethyl snlfoxide and N,N-diisopropylethylamine (0.7 ~tL) \Vere subsequently added under argon. The reaction was allowed to proceed in the dark under argon \Vith constant stining overnight. The reaction 1nixture \Vas dialyzed against water three times via a 3-kDa membrane centrifuge filter device (Amicon), The retentate \Vas then filtered through a 0.2 µm filter (Palls) and lyophilized to yield a yellow colored product.
Synthesis of AD·PEG·mannose
Three one hundredths millimoles of H-hydroxysuccinintlde-PEG-1naleintlde was added to 0.18mmol of 4-anlinophenyl alpha-D-mannopyranoside in phosphate-buffered saline (PBS), pH 7.5, and incubated for 1 hour at room temperature. Reaction mixture was then dialyzed against water, 0.lµm, and lyophilized. One hundred nine milliggrams of mannose-PEG-maleirnide and 13.3 mg of admantane-SH were dried under vacuum for 1 hour; 2 n1L of anhydrous dimethyl sulfoxide \Vas then added under inert gas and reaction was incubated overnight at room temperature. Water was added and insoluble material \Vas removed by centrifugation. The supernatant \Vas dialyzed against \Vater and 0.2 pm filtered and purified over 2x TSKgel G3000SWxl columns with PBS pH 7.2 at 0.5 rnIJrninute as the eluent. The appropriate fraction was collected and lyophilized. Structure was verified by proton nuclear magnetic resonance and matrix assisted laser desorption ionization time-of~ftight ( Supplementary Fig. S2 ). 
Cell culture
SV40-MES
In vivo EGFP knockdown experiment
Mice received i.v. doses of transferrin-targeted siRNAJ CDP NPs containing control siRNA (siCON), transferrintargeted siRNA/CDP NPs containing siEGFP, or nlannosetargeted siRNA/CDP NPs containing siEGFP at a dose of 10 mg/kg siRN A on day 1 and 3 of the experiment. Mice were killed on day 5 for kidney harvesting and tissue processing. Slides \Vere imaged in a blinded fashion with fixed detector gain; 70-72 consecutively identified glon1eruli from each slide were ilnaged. Data sets were scored prior to unblinding.
Transmission electron m;crocopy
Tissue blocks (,...., 1 mm 3 ) \Vere fixed in 2.5% glutaraldehyde (in 0.1 M sodium cacodylate, pH=7.4) for 2 hours, stained by 1 % Os0 4 at 4°C for 2 hours, and 0.9% osmium tetroxide (Os0 4 ) and 0.3% potassium ferrocyanide at 4°C for 2 hours. Gradual dehydration \Vith ethanol and propylene oxide enabled tissue embedding in Epon 812 resins (Electron Microscopy Sciences); 80·nm-thick sections were deposited on carbon and formvar-coated, 200-n1esh, nickel grids and stained \Vith 3% uranyl acetate and Reynolds lead citrate for visualization under a 300 kV TF30UT transmission electron microscope.
Fluorescent microscopy
Sections \Vere deparrafinized \Vith xylene, rehydrated, and mounted with ProLong Gold antifade reagent (Invitrogen) for viewing.
Confocal microscopy
Images \Vere obtained on a Zeiss LSM 510 inverted confocal scanning microscope (with a Zeiss PlanApochorn1atx 63/1.4 oil objective). The anti-CD90fihyl (MRC OX-7) mouse monoclonal antibody (Abeam: ab225) was used at 1:100 dilution. The excitation wavelength for AF350-CDP and 4' ,6-diamidino-2-phenylindole was 705 nm (two-photon laser) and 543 nm (helium-neon laser) for Cy3-siRNA. Their corresponding emission filters \Vere 390--465 nm, and 565-615 nm respectively. The measured resolution at which images \Vere acquired is 512x512 pixels, and the image bitdepth is 8 bits. The Zeiss LSM Image Browser Soft\vare allo\vs the extraction of in1ages.
Epifluorescent microscopy
Images \Vere obtained on an Olympus IXSO fluorescent microscope (\vith an Olympus UPlanfiuor 40X/1.3 oil ob· jective).
Magnetic bead based g/omeru/ar Isolation
Glomeruli were isolated using the method developed by Takemoto et al. [16] . Briefly, mice were perfused with Dynabeads (M-450 tosylactivated) (Invitrogen) suspended in PBS immediately post mortem via infusion through the left ventricle. Kidneys \Vere subsequently minced \Vith a razor blade follo\ved by digestion \Vith collagenase and DNaseI for 1 hour at 37°C. Digested material \Vas passed through two 5 µm cell strainers (BD bioscience) and pooled \Vith subsequent PBS \vashes of the strainers. Material was pelleted at 200 g for 10 minutes. The supernatant was decanted and the pellet resuspended in PBS. The tube containing the resuspended pellet \Vas placed on the magnet (Invitrogen) and the magnet bound material was washed three times with PBS. Magnet bound material \Vas resuspended in PBS and confinned to contain glomeruH via light microscopy,
RNA isolation and real Ume reverse transcription polymerase cha;n reaction
Total RNA was isolated from cells using the miRNeasy kit (Qiagen) following n1anufacturer's instructions and quantified using a Nanodrop 2000 spectrophotometer (Thermo). Custom Taqman n1icroRNA quantitative polymerase chain reaction (PCR) assays (Applied Biosystems) for siTrace \Vere used for quantification of siRNA frorn total RNA. Reverse transcription and PCR reactions were performed as described in the product manual. Real-time PCR analysis was performed using a MyiQ Single Color Real Time PCR Detection System (Bio-Rad).
Results
Rapid siRNA nanoparlicle internalization observed for mouse and human mesnagia/ cells in vitro
To den1onstrate the feasibility that human and 1nouse mesangial cells will internalize siRNA/CDP·NPs, we examined the uptake of siRNA/CDP-NPs by mesangial cells in vitro using Cy3-siRNA containing siRNA/CDP-NP forn1ul3.tions. Cy3-siRNA fluorescence intensity \Vas measured via both epiftuorescence nlicroscopy and flow cytometry. Both mouse and human mesangial cells internalized the siRNAfCDP-NPs, but not free siRNA, after only 5 minutes of exposure ( Fig. 2A; Supplementary Fig. S3A, B) . We confirmed these observations via flow cytomerty (Fig 2B) . \Ve also observed siRNA/CDP-NP uptake in rat mesangial cells ( Supplementary Fig. S3C ).
Intravenously administered siRNNCDP nanopartic/es deposit within the mouse kidney mesangium
To detern1ine whether i.v. adntlnistered siRNAJCDP-NPs deposit in the mesangium, we interrogated the level of fluorescent signal present in fixed sections of kidney tissue from mice that received i.v. siRNA/CDP-NPs that contain fluorescent components (Cy3-labed siRNA and AF350-labeled CDP). Fluorescent signal in the kidney after i.v. administration of free Cy3-siRNA Vt 1 as found \Vi thin tubule cells at 10 rninutes after injection and was nearly undetectable 120 minutes after injection (Fig. 3A) . No detectable fluorescence signal \Vas observed in the glomeruli of these 1nice. Ho\vever, following i.v. administration of Cy3-siRNA/CDP-NPs the opposite phenomenon was observed. Strong Cy3-siRNA fluorescence signal \Vas detected within all glomeruli examined at 10 minutes post injection, with minimal signal in tubule cells (Fig. 3A) . Although greatly attenuated, Cy3-siRNA fluorescent signal \Vas still clearly detectable in glo1neruli 120 minutes after i.v. administration \Vith minimal accumulation in other kidney compartments. \Ve also observed some fluorescent signal in the peritubule interstitial space follo\ving siRNA/CDP-NP administration, but not free siRNA administration (Supplementary Fig. S4 ).
To determine whether these siRNA/CDP-NP formulations were depositing as intact nanoparticles in the glomentlus, we examined the glome1ular fluorescent signal from mice receiving siRNA/CDP-NP forn1ulations containing both Cy3-siRNA and AF350-CDP (Fig. 3B) . Strong AF350-CDP fluorescence that colocalized \Vith the Cy3-siRNA signal \Vas observed in glomen1li at 10 minutes after injection. Although greatly attenuated, colocalized glomerular Cy3-siRNA and AF350-CDP fluorescence \Vas still detected in alJ glome1uli at 120 minutes post dose. \Ve confirmed these observations by transmission electron microscopy analyses that revealed electron dense objects in the glo1nerular capillary wall consistent in size and shape \Vith intact siRNA/CDP-NPs (Fig.  3C) .
To confinn delivery of siRNA/CDP-NPs to the mesangium, \Ve counter-stained tissue sections from mice that received Cy3-siRNA containing nanoparticles with the n1e-sangial marker thymie antigen I (Thy!) using the OX-7 monoclonal antibody (Fig. 3D) . We found persistent Cy3-siRNA fluorescent signal 48 hours after administration of the siRNA/CDP-NPs that colocalized with the OX-7 antibody staining. Semiquantitative colocalization analysis of Cy3-siRNA fluorescence and OX-7 staining using BiolmageXD soft\vare revealed 88o/o OX7 staining colocalization \Vith Cy3-ftuorescnece and 91 % colocalization of Cy3-siRNA fluorescence with OX-7 staining. These data suggest that siRNA/CDP-NP deposition in the glomerulus is primarily mesangial.
Outside the kidney, siRNNCDP-NPs have restricted distribution to liver sinusoids, and splenlc red pulp
The restricted biodistribution of nanoparticle therapeutics is paramount in limiting their off-target toxicities. Therefore, Global brightness and contrast \Vere adjusted across whole ilnages to improve clarity of images on scale for publication. Color images available online at \V\V\V.liebertpub.com/nat we explored the deposition of the Cy3-siRNA/CDP-NPs in other organs (Fig. 4) . Bright and diffuse Cy3-siRNA fluorescent signal was observed in liver and spleen, \vhereas only focal areas of fluorescent signal nearly indistinguishable from tissue background autofluorescence were observed in the lung, heart, and pancreas. Moreover, the suborgan level distribution in the liver and spleen \Vas also restricted. In the liver, the Cy3-siRNA fluorescent signal localized to sinusoids, whereas in the spleen, Cy3-siRNA fluorescent signal was found solely in the red pulp. The addition of the targeting ligands n1annose or transferrin to the siRNA/CDP NPs resulted in a mild increase in liver and spleen deposition ( Supplementary Fig. SS) . Our results are consistent with previously reported data from real-time positron emission tomography studies that showed siRNA/CDP-NPs primarily depositing in liver and kidney [17] .
Surface targeting ligands increase mesangial cell uptake of siRNAICDP-NPs in vitro and alter lntraglomerufar distribution in vitro
Surface targeting ligands have been demonstrated to improve the cellular internalization efficiencies of nanoparticles [18] . We hypothesized that addition of a targeting ligand to the siRNA/CDP-NPs \vould result in increased mesangial cell uptake. Therefore, \Ve tested mesangial cell uptake of siRNNCDP-NPs formulated \Vith t\VO different surface targeting ligands: (I) the sugar mannose and (2) the iron transport protein, transferrin. \Ve chose the mannose targeting ligand because, \Vithin the kidney, the expression of the mannose receptor (MR) is restriction to mesangial cells [19, 20] . The transfen·in targeting ligand \Vas chosen because \Ve have previously demonstrated its ability to enhance intracellular uptake of the siRNA/CDP-NPs in other cell lines in vitro and in vivo [17, 21] . Ho\vever, transferrin receptor is a niore general receptor expressed by many cell types, but not highly in the healthy glomerulus [22] .
Epifluorescence experiments qualitatively demonstrated similar n1esangial cell uptake for the targeted siRNA/CDPNPs as compared \Vith nontargeted nanoparticles ( Fig. 2A) . To more carefully quantify the amount of intracellular Cy3-siRNA fluorescence, we employed fl.ow cytometry (Fig. 2B) . (Fig. 4C, D) and quantitative PCR measurements (Fig. 5) \Vere used in these studies. Epifluorescence microscopy imaging was used to examine the distribution and intensity of the Cy3-siRNA fluorescence signal in glomeruli at 10 and 120 minutes after i.v. administration of untargeted siRNA/ CDP-NPs and mannose-targeted siRNNCDP-NPs (Fig. SA) . At 120 minutes after i.v. administration there \Vas a marked attenuation in glomerular fluorescent signal in kidneys fron1 mice treated \Vith untargeted siRNAJCDP-NPs. This attenuation in glomerular signal at 120 ntlnutes post treatn1ent \Vas was adjusted for maxin1al dynamic range or until diffuse background autofluorescence in proxi1nal tubules was apparent. In1ages with more visible background are lo\ver in overall fluorescence intensity. Global brightness and contrast were adjusted across whole images to improve clarity of images on scale for publication. Color images available online at \V\V\V.liebertpub.com/nat not observed in the kidneys of mice treated with mannosetargeted siRNNCDP-NPs. These data suggest that mannose targeting of nanoparticles resulted in a longer glon1erular residency time for the rnannose-targeted siRNA/CDP-NPs. Figure 5B demonstrates that glomentlar fluorescence intensity at 120 minutes post treatment in the kidneys of mice treated \Vith transferrin-targeted siRNA/CDP-NPs \Vas similar to untargeted siRNA/CDP-NPs and markedly less than the fluorescence intensity of the mannose-targeted siRNA/CDPNPs. These data suggest that inclusion of a transferrin targeting ligand did not result in longer glomerular residency times for the siRNA/CDP-NPs. To more quantitatively assess delivery of targeted siRNA/ CDP-NPs to the glomerulus, we used quantitative PCR to interrogate the level of siRNA present in isolated glomeruli from mice receiving i.v. administration of the different siR-NA/CDP-NP formulations (Fig. 6 ). siRNA present in whole RNA extracts from these glomen1li \Vas detected using a custom Taqman real-time PCR probe to detect the presence of the antisense strand of a specific siRNA sequence (siTrace). Glomerular RNA extracts fro1n mice treated \vith transferrin-targeted siRNA/CDP-NP \Vith a control siRNA sequence (siCON) that is not recognized by the Taqman PCR probe \Vere used as background controls.
CDP-NPs. Fluorescence rnicrocopy on fixed tissue sections
\Ve first examined the glomen1li from mice 1 and 3 days after received i.v. doses of free siTrace. At 1 day post dose, siTrace \Vas detectable in RN A extracts from these glorneruli at levels 12-fold above background. At 3 days post dose, siTrace signal in glornerular RNA extracts from this treatment group were not significantly above background. \Ve next examined glornen11i from mice that received iv. doses of various siRNA/CDP-NP formulations. At 1 day post dose, siTrace signal in glomerular RNA extracts fro1n the nontargeted siRNA/CDP-NP treatment group was found to be 333-fold higher than the siTrace signal detected in the free siTrace treatment group. The amount of siTrace signal in the glorneruli from mice treated with transferrin-or mannose-targeted siRNA/CDP-NPs (356-and 274-fold above background respectively) was not significant different from the amount detected in the nontargeted siRNA/CDP-NP group. At 3 days post dose, siTrace signal in the glomeruli fro1n both the transferrin-and mannose-targeted siRNNCDP-NPs \Vas still significantly higher than siTrace signal detected in the free siRNA treatment group. Although transferrin-targeting lead to a 12-fold increase in total siTrace signal in glomeruli compared \Vith mannose targeting, these results \Vere not significantly different.
siRNAICDP-NPs silenced gene expression in the mesangium
\Ve next examined th~ ability oftransferrin-and mannosetargeted siRNNCDP-NPs to silence EGFP expression in the p<0.05
. . . . (Fig. 7) . A microscopybased analysis \Vas chosen to facilitate specific analysis of mesangial EGFP expression. \Ve used a blinded, semiquantitative, glomerular fluorescence scoring analysis to determine the level of EGFP expression in the glomerulus. Fluorescence micrographs of 70-72 glomeruli from each mouse \Vere taken and scored as high, intennediate, or lo\v EGFP fluorescence (representative examples of each scoring category are pictured in Supple1nentary Fig. S6C ).
Once scores had been assigned to all imaged glomeruli, the data \Vere unblinded and results from each treatment group \Vere averaged and cotnpared. Kidneys from mice receiving the siRNA/CDP-NPs containing control siRNA (siCON) Supplementary  Fig. S2 ). All in1aging and sco1ing were performed blind. The average nun1ber of glomeruH fron1 each scoring bin are sho\vn, Error bars are standard deviation; n=3; p values are results of one-tailed t-tests. Color in1ages available on1ine at W\VW.liebertpub .co1n/nat was noted only in the tnannose-targeted siRNA/CDP-NP treatment group. Altogether, these data demonstrate gene knockdo\vn in the mesangium follo,ving i.v. siRNA/CDP-NP adtninistration.
Discussion
Taken in total, the results from our studies demonstrate the feasibility of siRNA delivery to the mesangiu1n following i.v. administration of siRNA/CDP-NPs. Using confocal tnicroscopy, \Ve demonstrated the presence of Cy3-siRNA in the glomeruli of mice that received i.v. doses of siRNA/CDPNPs, but not in the glomeruli of mice that received free siRNA. Additionally, we showed that the siRNA/CDP-NPs deposit in the g1on1erulus as intact nanoparticles as evidenced by the colocalization of Cy3-siRNA and AF350-CDP fluorescence in the glomerulus as \Vell as electron micrographs of nanoparticle sized objects in the glomerular capillary \Vall.
Colocalization of Cy3-siRNA fluorescence and OX-7 antibody staining for Thyl antigen confirmed mesangial delivery of the siRNA. Biodistribution studies demonstrated a restricted deposition outside the kidney Ii1nited to liver sinusoids (likely in Kupffer cells [23] ) and splenic red pulp.
Fu1ihermore, ,ve demonstrated that both 111ouse and human 1nesangial cells can rapidly internalize the siRNA/CDP-NPs but not free siRNA in vitro and that uptake of the siRNA/ CDP-NPs by mesangial cells can be enhanced by surface targeting ligands. Lastly, \Ve sho\ved that i.v. doses of siRNA/ CDP-NPs resulted in decreased mesangial expression of EGFP in a EGFP-reporter mouse strain.
To our kno\vledge, our study is only the second reported example of polymer-nanoparticle mediated siRNA delivery to the mesangium following systentic administration. The first, perfonned by Shimizu et al. den1onstrated that nontargeted 10-nm siRNA/cationic polymer micelles can reach the glomen1lus foJJo,ving intraperitoneal administration (10] . Our study builds upon this \VOrk by demonstrating the feasibility of using i. v. adntinistration as \vell as larger ( ~ 70 nm) polymer-based nanoparticles to target the mesangium. Moreover, the siRNA/CDP-NPs used here have previously been demonstrated to deliver function siRNA to patient tumor tissue follo\ving i.v. administration in the clinic, and therefore the results presented here have direct translational relevance. \Ve suggest that the siRNA/CDP-NPs could be useful for mesangial delivery of siRNA in humans. Given that the ultrastructure of the glomentlus across mammalian species is nearly identical [24] , we speculate that our observations in the mouse kidney would be applicable to delivery to htunan kidney inesangium. Also, we showed that human n1esangial cells n1ore readily uptake the siRNA/CDPNPs than n1ouse mesangial cells in vitro.
\Ve investigated if the surface targeting ligands transferrin or mannose could be used to increase mesangial uptake of the siRNA/CDP-NPs. Mannose receptor expression in the kidney is restricted to the mesangium [19, 20] and has been demonstrated to facilitate uptake of nanoparticles by macrophages in vivo (25, 26] . The transfeni.n receptor, although up-regulated \Vithin the mesangium of patients \Vith lgA nephropathy [27] [28] [29] , is not highly expressed in the healthy glomerulus, but has been den1onstrated to facilitate intracellular uptake of the transferrin-targeted siRNNCDP-NPs in other cell lines [17, 21] .
In vitro, the rnannose targeting ligand enhanced uptake of the siRNNCDP-NPs in both n1ouse and human mesangial cells, \Vhereas the transferrin receptor only enhanced uptake in n1ouse cells. In vivo, mannose targeting resulted in enhanced glomerular Cy3-siRNA fluoresce intensity 2 hours after i. v. dosing compared \vi th either untargeted or transfenintargeted siRNA/CDP-NPs. However, these effects were transient as the total amount of siRNA detected in isolated glomeruli by PCR 1 day follo\ving i.v. administration \Vas not different among the various siRNAfCDP-NP formulations. Shnilarly, rnannose targeting did not result in any additional benefit in the EGFP knockdo\vn experiment. Surprisingly, the PCR quantification data of siRNA delivery to the glon1erulus at 3 days post dose trended higher for the transferrinsiRNNCDP NP group compared with the mannose-siRNN CDP NP group (although statistical significance was not achieved). These data suggest that transferrin may be the superior targeting ligand for mesangial targeting. We speculate ZUCKERMAN ET AL.
that mannose targeting may favor trafficking to digestive compartments \Vithin the mesangial cell resulting in more rapid degradation of the siRNNCDP-NPs. Nontargeted, transferrin-targeted, and some fraction of the mannose-targeted siRNNCDP-NPs may be taken up through alternate pathways (e.g., endocytosis, macropinocytosis, calveolar transport) that are more pennissible for endosomal escape and subsequent siRNA delivery to the cytoplasm (18] . Further \Vork to elucidate this mechanism is merited.
Several other non-nanoparticle based strategies of siRNA delivery to the kidney glomerulus have been reported. Hauser et al. have demonstrated that a monovalent lg-protamine conjugate could successfully deliver siRNA to normal murine podocytes in vivo {11]. Yuan et al., have also sho\vn that subcutaneous administration of cholesterol conjugated phosphorothioate-modified siRNAs targeting 12/15-lipoxegenase reduced kidney damage in diabetic mice [30] . Other reported examples of siRNA delivery to the glomerulus and kidney in general have employed less clinically applicable direct renal artery injections [31] . Nanoparticle n1edi-ated delivery of siRNA can be advantageous over these methods due to the highly tunable nature of their pharn1a-cokinetic, biodistribution, and targeting properties compared with free antibodies, phosphorothioate-modified, or other free nucleic acids. Theoretically, these properties of nanoparticles should enable more specific control of targeting and off-target effects.
Our study has several limitations. \Ve confined our experiments to healthy mice. It remains to be detennined whether the siRNA/CDP NP system can facilitate gene knockdown in mouse n1odels of kidney disease. Ho\vever, reports examining nanoparticle delivery to the diseased kidney in animal models (6,9,32~35] suggest that nanoparticles have a higher propensity for glomerular deposition in glon1en1lonephritic states, likely due to increased vascular permeability and inflammation. Thus, the healthy, rather than the diseased kidney, may provide the more restrictive condition for nanoparticle delivery. Furthermore, many chronic kidney diseases such as diabetic nephropathy display fairly subtle glomerular morphologic changes in early disease, and \Ve speculate that the glon1erular nanoparticle targeting criteria may not be significantly altered until advance stage disease. Another limitation of the current study is that \Ve only reported mesangial knockdo\vn of a reporter protein (EGFP) in a transgenic mouse 1nodel rather than an endogenous, biologically relevant, mesangial protein. \Ve have performed follow-up experhnents that demonstrate knockdo,vn of the endogenous mesangial protein Orailin mice [36] . Therefore, \Ve believe the knockdown of EGFP repo11ed in this study \Vill be generalizable to other mesangial protein targets. 
